Clinical significance and prevalence of T315I mutation in Imatinib Mesylate resistance in Indian Chronic Myeloid Leukemia patients. (First study from India)

被引：0
|
作者：
Mir, Rashid [1 ]
Sazawal, S. [1 ]
Chobey, R. [1 ]
Bohra, B. [1 ]
Bharti, S. [1 ]
Ravi, K. [1 ]
Pravas, M. [1 ]
Mehraj, Q. [2 ]
Yasrib, M. [2 ]
Mudasir, T. [2 ]
Shyam, R. [1 ]
Saxena, R. [1 ]
机构：
[1] All India Inst Med Sci, Dept Haematol, New Delhi, India
[2] Univ Kashmir, Srinagar 190006, Jammu & Kashmir, India
来源：
JOURNAL OF MEDICAL GENETICS | 2008年 / 45卷
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
引用
收藏
页码：S112 / S112
页数：1
相关论文
共 50 条
  • [21] Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation
    Benichou, A.
    Khoury, H. J.
    Corm, S.
    Nicolini, F. E.
    Craig, A. R.
    Humphriss, E.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [22] Rapid Quantitative Detection of the T315I Mutation in Patients With Chronic Myelogenous Leukemia
    Yin, Lihui
    Dittman, David
    Chenn, Anjen
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2012, 21 (01) : 34 - 39
  • [23] T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia
    Kimura, Kenji
    Tsukamoto, Shokichi
    Takaishi, Koji
    Isshiki, Yusuke
    Kayamori, Kensuke
    Hino, Yutaro
    Ohshima-Hasegawa, Nagisa
    Mitsukawa, Shio
    Takeda, Yusuke
    Mimura, Naoya
    Takeuchi, Masahiro
    Ohwada, Chikako
    Iseki, Tohru
    Nakaseko, Chiaki
    Sakaida, Emiko
    LEUKEMIA & LYMPHOMA, 2019, 60 (06) : 1591 - 1594
  • [24] Patients with chronic myeloid leukemia resistant to the inhibitors of tyrosine kinase with the T315I mutation should be treated by Allograft
    Fouillard, Loic
    HEMATOLOGIE, 2010, 16 (04): : 277 - 278
  • [25] Gene expression signatures associated with treatment and resistance to imatinib mesylate in chronic myeloid leukemia patients.
    Oehler, V
    Branford, S
    Pogosova-Agadjanyan, E
    Shah, N
    Sawyers, C
    Mao, M
    Linsley, P
    Hughes, T
    Radich, J
    BLOOD, 2005, 106 (11) : 131A - 131A
  • [26] PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia
    Gupta, Pranav
    Kathawala, Rishil J.
    Wei, Liuya
    Wang, Fang
    Wang, XiaoKun
    Druker, Brian J.
    Fu, Li-Wu
    Chen, Zhe-Sheng
    CANCER LETTERS, 2016, 383 (02) : 220 - 229
  • [27] Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment
    Minami, Yosuke
    Kajiguchi, Tomohiro
    Abe, Akihiro
    Ohno, Toshihito
    Kiyoi, Hitoshi
    Naoe, Tomoki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (04) : 664 - 666
  • [28] The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation
    Zhang, Hao
    Liang, Zuyu
    Hu, Yongxian
    Wang, Xiujian
    Wang, Binsheng
    Huang, He
    LEUKEMIA & LYMPHOMA, 2018, 59 (12) : 3018 - 3019
  • [29] HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia
    Yun, Sun-Mi
    Jung, Kyung Hee
    Kim, Soo Jung
    Fang, Zhenghuan
    Son, Mi Kwon
    Yan, Hong Hua
    Lee, Hyunseung
    Kim, JinHee
    Shin, Sanghye
    Hong, Sungwoo
    Hong, Soon-Sun
    CANCER LETTERS, 2014, 348 (1-2) : 50 - 60
  • [30] Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment
    Yosuke Minami
    Tomohiro Kajiguchi
    Akihiro Abe
    Toshihito Ohno
    Hitoshi Kiyoi
    Tomoki Naoe
    International Journal of Hematology, 2010, 92 : 664 - 666
12345